IR@PKUHSC  > 北京大学第二临床医学院  > 胸外科
学科主题临床医学
Tolerability and toxicity of adjuvant cisplatin and gemcitabine for treating non-small cell lung cancer
Yang Fan; Li Xiao; Chen Ke-zhong; Jiang Guan-chao; Wang Jun
关键词Non-small Cell Lung Cancer Adjuvant Drug Therapy Toxicity Tolerability
刊名CHINESE MEDICAL JOURNAL
2013-06-05
DOI10.3760/cma.j.issn.0366-6999.20130309
126期:11页:2087-2091
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Medicine, General & Internal
研究领域[WOS]General & Internal Medicine
关键词[WOS]VINORELBINE PLUS CISPLATIN ; DOSE INTENSITY ; 1ST-LINE TREATMENT ; PHASE-III ; CHEMOTHERAPY ; TRIAL ; METAANALYSIS ; IMPACT
英文摘要

Background The combination of cisplatin and vinorelbine is an evidence-supported regimen for adjuvant chemotherapy for treating non-small cell lung cancer (NSCLC). But this doublet has considerable toxicity and unfavorable tolerability, and results in poor compliance. The cisplatin and gemcitabine regimen is one of the most active and well-tolerated regimens against advanced NSCLC, but its toxicity and tolerability has not been adequately evaluated in the adjuvant setting.

Methods From a lung cancer database we retrospectively reviewed NSCLC patients receiving adjuvant chemotherapy of cisplatin (75 mg/m(2)) and gemcitabine (1250 mg/m(2)) between January 2005 and December 2011. Postoperative demographics, compliance to adjuvant therapy and toxicity were retrieved from medical records.

Results A total of 132 patients met the criteria and were included in the study, 96 were male (72.7%) and 36 were female (27.3%). Median age was 60.5 years old, range 29-75 years, and 41.7% of patients were >= 65 years old. Overall, 68.2% patients received all four planned cycles, and the cumulative dose delivered for gemcitabine was 8333 mg (83.3% of the planned dose) and cisplatin 248 mg (82.7% of the planned dose). There were no treatment-related deaths. Grade 3/4 neutropenia developed in 47 patients (35.6%) and was the predominant hematologic toxicity. Common grade 3/4 non-hematologic toxicities were nausea/vomiting (22.0%), infection (12.3%), and febrile neutropenia (11.4%).

Conclusion Cisplatin and gemcitabine are feasible for use in the adjuvant setting with a favorable toxicity profile and superior tolerability compared with published data on cisplatin and vinorelbine.

语种英语
WOS记录号WOS:000321473700017
引用统计
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/58060
专题北京大学第二临床医学院_胸外科
北京大学基础医学院
北京大学第一临床医学院_眼科
作者单位Peking Univ, Peoples Hosp, Dept Thorac Surg, Beijing 100044, Peoples R China
推荐引用方式
GB/T 7714
Yang Fan,Li Xiao,Chen Ke-zhong,et al. Tolerability and toxicity of adjuvant cisplatin and gemcitabine for treating non-small cell lung cancer[J]. CHINESE MEDICAL JOURNAL,2013,126(11):2087-2091.
APA Yang Fan,Li Xiao,Chen Ke-zhong,Jiang Guan-chao,&Wang Jun.(2013).Tolerability and toxicity of adjuvant cisplatin and gemcitabine for treating non-small cell lung cancer.CHINESE MEDICAL JOURNAL,126(11),2087-2091.
MLA Yang Fan,et al."Tolerability and toxicity of adjuvant cisplatin and gemcitabine for treating non-small cell lung cancer".CHINESE MEDICAL JOURNAL 126.11(2013):2087-2091.
条目包含的文件
文件名称/大小 文献类型 版本类型 开放类型 使用许可
Tolerability and tox(88KB)期刊论文出版稿开放获取CC BY-NC-SA浏览 请求全文
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Yang Fan]的文章
[Li Xiao]的文章
[Chen Ke-zhong]的文章
百度学术
百度学术中相似的文章
[Yang Fan]的文章
[Li Xiao]的文章
[Chen Ke-zhong]的文章
必应学术
必应学术中相似的文章
[Yang Fan]的文章
[Li Xiao]的文章
[Chen Ke-zhong]的文章
相关权益政策
暂无数据
收藏/分享
文件名: Tolerability and toxicity of adjuvant cisplatin and gemcitabine for treating non-small cell lung cancer.pdf
格式: Adobe PDF
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。